Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EPR Properties (EPR) vs 10X Genomics Inc (TXG) Price & Performance

EPR PropertiesTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

EPR Properties vs 10X Genomics Inc — how do they compare? EPR Properties trades at $61.69 (market cap $4.60B), while 10X Genomics Inc trades at $45.25 (market cap $5.81B). The key difference: 10X Genomics Inc is the larger of the two by market cap, and EPR Properties pays a 6.19% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

EPRTXG
Market Cap
$4.60B$5.81B
Sector
Real EstateHealth
52-Week High
$60.81$45.80
52-Week Low
$48.71$11.34
Enterprise Value
$7.66B$5.35B
Dividend Yield
6.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

EPR Properties

EPR Properties (EPR) trades at $61.80, up 3.8% over 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $63.25. The REIT maintains strong profitability with a 39.93% net income margin and 10.68% ROE, supported by recent earnings beats and a strategic shift toward experiential assets like the $315 million Six Flags acquisition. Monthly dividends of $0.31 provide a steady income stream, with Q2 2026 earnings results due July 29, 2026.

Outlook remains positive due to high occupancy, dividend yield, and portfolio diversification, but risks include reliance on consumer spending and potential interest rate impacts. Analyst sentiment is mixed with a hold-heavy consensus, suggesting cautious optimism for income-focused investors amid stable fundamentals.

10X Genomics Inc

TXG is trading at $45.80, up 9.65% today, showing strong momentum despite mixed analyst sentiment. The stock exhibits bullish technical signals with positive moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, the company continues to report revenue growth with improving margins, narrowing losses from -$166M in 2022 to -$44M in 2025. Recent developments include strategic acquisitions and research collaborations that strengthen its life sciences technology position.

The outlook remains cautiously optimistic as TXG demonstrates operational improvement and strategic positioning in genomics technology. Key opportunities include continued margin expansion and platform adoption, while risks involve persistent profitability challenges and competitive pressures. Analyst consensus shows divided opinions with a $37.71 price target below current levels, suggesting potential near-term volatility despite long-term growth prospects.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About EPR Properties

EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.

Read more on EPR

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG